Many medications are used in the critical care setting. A comprehensive assessment of a patient’s clinical status, comorbid conditions, and current medications is necessary before additional interventions are applied. All medical interventions should be evidence-based, goal-directed therapy. Because critical care pharmacotherapy literature evolves rapidly, practitioners must be vigilant to stay up to date with new guidelines and best practices.
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Florida Board of Nursing (CEBroker Provider #50-290)
This is not an accredited course for professional license renewal. Florida CNAs may use this inservice toward meeting their annual inservice requirement.
Georgia Board of Nursing (CEBroker Provider #50-290)
Kansas State Board of Nursing (CEBroker Provider #50-290)
Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.50 contact hours for participating in this course.
Louisiana State Board Of Medical Examiners - Midwifery (CEBroker Provider #50-290)
Michigan Board of Nursing (CEBroker Provider #50-290)
Mississippi Board of Nursing (CEBroker Provider #50-290)
New Mexico Board of Nursing (CEBroker Provider #50-290)
New Mexico Certified Nurse Midwives and Licensed Midwives (CEBroker Provider #50-290)
North Dakota Board of Nursing (CEBroker Provider #50-290)
South Carolina Board of Nursing (CEBroker Provider #50-290)
West Virginia Board of Registered Nursing (CEBroker Provider #50-290)
Wyoming Board of Nursing (CEBroker Provider #50-290)
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Vasopressors and Inotropes
Overview
Pure Vasopressors
Inopressors
Inodilators
New Vasopressor Agents
Section 3: Antihypertensives
β-Adrenergic Receptor Blockers
Calcium Channel Blockers (CCBs)
Angiotensin-Converting Enzyme (ACE) Inhibitors
Other Agents
Vasodilators
Pulmonary Vasodilators
Section 4: Anti-Arrhythmics
Overview
Class 0: Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blockers
Class I: Voltage-Gated Sodium Channel Blockers
Class II: Autonomic Inhibitors and Activators
Class III: Potassium Channel Blockers and Openers
Class IV: Calcium Channel Modulators
Class V: Mechanosensitive Channel Blockers
Class VI: Gap Junction Channel Blockers
Class VII: Upstream Target Modulators
Section 5: Hemostatic Drugs
Overview
Anticoagulants
Antiplatelet Drugs
Thrombolytics
Antifibrinolytics and Hemostatic Agents
Section 6: Conclusion
Course Summary
Course Contributors
References
Reviewer: Derek J. Gyllenhammer, PharmDEmily is a graduate of UNC Wilmington, where she earned an MSN in Nursing Education in 2021. She is an experienced perianesthesia care unit (PACU) nurse and has cared for a wide variety of inpatient and ambulatory surgical patients. Emily has served as a Charge Nurse in UNC’s Ambulatory Care PACU and holds her CPAN certification from the American Board of Perianesthesia Nursing Certification (ABPANC). Her passion for education has led her to a position as a content writer at Relias.
Derek J. Gyllenhammer, PharmD, is a community pharmacist from the Hartford, Connecticut, area. He graduated with his Doctor of Pharmacy from the University of Connecticut in 2016.
Access to over 1,450 courses! Access to 1,450+ courses for one low price.